Evidence map›Paper›PMID 27208618›Full record

ArticleNeuroscience2016

Prohormone convertase 2 (PC2) null mice have increased mu opioid receptor levels accompanied by altered morphine-induced antinociception, tolerance and dependence.

K Lutfy, D Parikh, D L Lee, Y Liu, M G Ferrini, A Hamid, T C Friedman

Open access · bronzeAbstract read
In one paragraph

Article in Neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

K LutfyDepartment of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA; Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Charles R. Drew University of Medicine and Sciences, Los Angeles, CA 90059, USA. Electronic address: klutfy@westernu.edu.
D ParikhDepartment of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA.
D L LeeDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Charles R. Drew University of Medicine and Sciences, Los Angeles, CA 90059, USA.
Y LiuDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Charles R. Drew University of Medicine and Sciences, Los Angeles, CA 90059, USA.
M G FerriniDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Charles R. Drew University of Medicine and Sciences, Los Angeles, CA 90059, USA.
A HamidDepartment of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA; Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Charles R. Drew University of Medicine and Sciences, Los Angeles, CA 90059, USA.
T C FriedmanDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Charles R. Drew University of Medicine and Sciences, Los Angeles, CA 90059, USA.
Charles R. Drew University of Medicine and Science · USWestern University of Health Sciences · US

Funding

Drew MIDARP (Infrastructure in Drug Abuse Research)R24DA017298 · NIDA · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI FRIEDMAN, THEODORE C · 2004 to 2018
$5.0M
The Role of Adipose H6PDH in Type 2 Diabetes and ObesitySC1DK104821 · NIDDK · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI LIU, YANJUN · 2014 to 2017
$1.3M
Genes and Proteins Leading to AddictionR01DA014659 · NIDA · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI FRIEDMAN, THEODORE C · 2002 to 2006
$1.1M
THE OFQ/N/ORL-1 RECEPTOR SYSTEM &COCAINE SENSITIZATIONR01DA016682 · NIDA · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI LUTFY, KABIRULLAH · 2004 to 2006
$513k
NIDA NIH HHS R01 DA014659NIDA NIH HHS R01 DA016682NIDA NIH HHS R24 DA017298NIDDK NIH HHS SC1 DK104821
6 · The paper itself

Abstract

Chronic morphine treatment increases the levels of prohormone convertase 2 (PC2) in brain regions involved in nociception, tolerance and dependence. Thus, we tested if PC2 null mice exhibit altered morphine-induced antinociception, tolerance and dependence. PC2 null mice and their wild-type controls were tested for baseline hot plate latency, injected with morphine (1.25-10mg/kg) and tested for antinociception 30min later. For tolerance studies, mice were tested in the hot plate test before and 30min following morphine (5mg/kg) on day 1. Mice then received an additional dose so that the final dose of morphine was 10mg/kg on this day. On days 2-4, mice received additional doses of morphine (20, 40 and 80mg/kg on days 1, 2, 3, and 4, respectively). On day 5, mice were tested in the hot plate test before and 30min following morphine (5mg/kg). For withdrawal studies, mice were treated with the escalating doses of morphine (10, 20, 40 and 80mg/kg) for 4days, implanted with a morphine pellet on day 5 and 3 days later injected with naloxone (1mg/kg) and signs of withdrawal were recorded. Morphine dose-dependently induced antinociception and the magnitude of this response was greater in PC2 null mice. Tolerance to morphine was observed in wild-type mice and this phenomenon was blunted in PC2 null mice. Withdrawal signs were also reduced in PC2 null mice. Immunohistochemical studies showed up-regulation of the mu opioid receptor (MOP) protein expression in the periaqueductal gray area, ventral tegmental area, lateral hypothalamus, medial hypothalamus, nucleus accumbens, and somatosensory cortex in PC2 null mice. Likewise, naloxone specific binding was increased in the brains of these mice compared to their wild-type controls. The results suggest that the PC2-derived peptides may play a functional role in morphine-induced antinociception, tolerance and dependence. Alternatively, lack of opioid peptides led to up-regulation of the MOP and altered morphine-induced antinociception, tolerance and dependence.

Indexed as

Analgesics, OpioidAnimalsBrainDose-Response Relationship, DrugDrug ToleranceMaleMice, 129 StrainMice, Inbred C57BLMice, KnockoutMorphineMorphine DependenceNaloxoneNarcotic AntagonistsNociceptive PainProprotein Convertase 2Receptors, Opioid, muAnalgesics, OpioidMorphineNaloxoneNarcotic AntagonistsPcsk2 protein, mouseProprotein Convertase 2Receptors, Opioid, muantinociceptionmorphinemu receptorsprohormone convertase 2 (PC2) null micetolerancewithdrawal signs

Identifiers

PMID27208618
PMCPMC4933571
OpenAlexW2398559086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.